Oncology News | pharmaphorum

News

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a fu

News

ASCO22: Enhertu aces key HER2-low test in breast cancer

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivo

News

BMS sets up Roche, Pfizer rivalry with Turning Point takeove...

Bristol-Myers Squibb's all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives it a lead asset that

News

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targ

News

Median Tech debuts AI-focused unit for cancer trial support

Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of clinical t

News

SEC accuses former AstraZeneca exec of insider trading

The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights to Daiichi Sankyo's breast

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

ASCO22: Enhertu aces key HER2-low test in breast cancer

BMS sets up Roche, Pfizer rivalry with Turning Point takeove...

Astellas taps GO's glycoprotein platform with $783.5m deal

Median Tech debuts AI-focused unit for cancer trial support

SEC accuses former AstraZeneca exec of insider trading

FDA hands another rejection to Replimune's melanoma therapy

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks